INOVA FAIRFAX HOSPITAL
1. Target Overview & Investment Thesis
INOVA FAIRFAX HOSPITAL is a 860-bed large academic medical center in FAIRFAX, VA with $2.41B in net patient revenue and a 20.5% operating margin. The hospital serves a payer mix of 23.6% Medicare, 11.6% Medicaid, and 64.8% commercial.
Thesis: Platform Growth. Our ML models identify $177.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 20.5% to 27.9% (+736bps).
| Net Revenue HCRIS | $2.41B |
| Current EBITDA COMPUTED | $495.1M |
| Operating Margin COMPUTED | 20.5% |
| Occupancy HCRIS | 91.1% |
| Revenue / Bed COMPUTED | $2.8M |
| Net-to-Gross HCRIS | 46.2% |
| Distress Probability ML | 42.3% |
2. Market Context & Competitive Position
VA has 111 Medicare-certified hospitals with a median operating margin of 4.4%. The target's margin of 20.5% places it above the state median. Among 9 size-comparable peers (430-1720 beds), the median margin is 1.4%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (430-1720), prioritizing same-state peers. 9 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| INOVA FAIRFAX HOSPITAL (Target) | VA | 860 | $2.41B | 20.5% |
| UNIVERSITY OF VIRGINIA MEDICAL | VA | 665 | $2.37B | 1.1% |
| VCU HEALTH SYSTEM MCV HOSPITAL | VA | 842 | $2.26B | 0.3% |
| CARILION MEDICAL CENTER | VA | 637 | $1.46B | -11.3% |
| SENTARA NORFOLK GENERAL HOSPIT | VA | 472 | $1.34B | 4.9% |
| CJW MEDICAL CENTER | VA | 612 | $1.00B | 32.8% |
| WINCHESTER MEDICAL CENTER | VA | 455 | $694.7M | -5.8% |
| HENRICO DOCTORS HOSPITAL | VA | 686 | $660.5M | 18.9% |
| MARY WASHINGTON HOSPITAL | VA | 440 | $552.1M | 1.7% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $177.4M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $50.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $48.2M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $47.7M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $29.3M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $1.5M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $495.1M |
| + RCM Uplift | +$177.4M |
| Pro Forma EBITDA | $672.6M |
| Current Margin | 20.5% |
| Pro Forma Margin | 27.9% |
| WC Released (1x) | $92.4M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $761.7M | $5.04B | 6.62x | 45.9% |
| Base (11x exit) | 10.0x | 11.0x | $761.7M | $5.79B | 7.60x | 50.0% |
| Bull Case | 9.0x | 11.0x | $685.6M | $6.62B | 9.66x | 57.4% |
| Bull (12x exit) | 9.0x | 12.0x | $685.6M | $7.43B | 10.84x | 61.1% |
| Bear Case | 11.0x | 10.0x | $837.9M | $3.91B | 4.66x | 36.0% |
| Bear (11x exit) | 11.0x | 11.0x | $837.9M | $4.57B | 5.45x | 40.4% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 9 hospitals with 430-1720 beds
- Same-state prioritization (n=10)
- Comp margins: P25=-1.3% / P50=1.4% / P75=8.4%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.